{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T21:22:12Z","timestamp":1789766532118,"version":"4.0.1"},"reference-count":110,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,12,3]],"date-time":"2015-12-03T00:00:00Z","timestamp":1449100800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,12,3]],"date-time":"2015-12-03T00:00:00Z","timestamp":1449100800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1038\/hr.2015.134","type":"journal-article","created":{"date-parts":[[2015,12,3]],"date-time":"2015-12-03T07:06:22Z","timestamp":1449126382000},"page":"183-191","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Current therapies and investigational drugs for peripheral arterial disease"],"prefix":"10.1038","volume":"39","author":[{"given":"Jun-ichi","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munehisa","family":"Shimamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Suda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouji","family":"Wakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Kumagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Akazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuaki","family":"Isobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issei","family":"Komuro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuichi","family":"Morishita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,12,3]]},"reference":[{"key":"BFhr2015134_CR1","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1177\/1358863X12438270","volume":"17","author":"GO Ouma","year":"2012","unstructured":"Ouma GO, Jonas RA, Usman MH, Mohler ER 3rd . Targets and delivery methods for therapeutic angiogenesis in peripheral artery disease. Vasc Med 2012; 17: 174\u2013192.","journal-title":"Vasc Med"},{"key":"BFhr2015134_CR2","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S0741-5214(89)70041-0","volume":"9","author":"MA Howell","year":"1989","unstructured":"Howell MA, Colgan MP, Seeger RW, Ramsey DE, Sumner DS . Relationship of severity of lower limb peripheral vascular disease to mortality and morbidity: a six-year follow-up study. J Vasc Surg 1989; 9: 691\u2013696.","journal-title":"J Vasc Surg"},{"key":"BFhr2015134_CR3","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1056\/NEJM199202063260605","volume":"326","author":"MH Criqui","year":"1992","unstructured":"Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, Browner D . Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992; 326: 381\u2013386.","journal-title":"N Engl J Med"},{"key":"BFhr2015134_CR4","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0021-9150(91)90014-T","volume":"87","author":"M McKenna","year":"1991","unstructured":"McKenna M, Wolfson S, Kuller L . The ratio of ankle and arm arterial pressure as an independent predictor of mortality. Atherosclerosis 1991; 87: 119\u2013128.","journal-title":"Atherosclerosis"},{"key":"BFhr2015134_CR5","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0950-821X(05)80925-9","volume":"5","author":"RB Klop","year":"1991","unstructured":"Klop RB, Eikelboom BC, Taks AC . Screening of the internal carotid arteries in patients with peripheral vascular disease by colour-flow duplex scanning. Eur J Vasc Surg 1991; 5: 41\u201345.","journal-title":"Eur J Vasc Surg"},{"key":"BFhr2015134_CR6","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/S0741-5214(94)70040-0","volume":"19","author":"RJ Valentine","year":"1994","unstructured":"Valentine RJ, Grayburn PA, Eichhorn EJ, Myers SI, Clagett GP . Coronary artery disease is highly prevalent among patients with premature peripheral vascular disease. J Vasc Surg 1994; 19: 668\u2013674.","journal-title":"J Vasc Surg"},{"key":"BFhr2015134_CR7","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1056\/NEJMoa041905","volume":"351","author":"EO McFalls","year":"2004","unstructured":"McFalls EO, Ward HB, Moritz TE, Goldman S, Krupski WC, Littooy F, Pierpont G, Santilli S, Rapp J, Hattler B, Shunk K, Jaenicke C, Thottapurathu L, Ellis N, Reda DJ, Henderson WG . Coronary-artery revascularization before elective major vascular surgery. N Engl J Med 2004; 351: 2795\u20132804.","journal-title":"N Engl J Med"},{"key":"BFhr2015134_CR8","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1177\/1358863X9700200310","volume":"2","author":"MH Criqui","year":"1997","unstructured":"Criqui MH, Denenberg JO, Langer RD, Fronek A . The epidemiology of peripheral arterial disease: importance of identifying the population at risk. Vasc Med 1997; 2: 221\u2013226.","journal-title":"Vasc Med"},{"key":"BFhr2015134_CR9","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1097\/01.RVI.0000137978.15352.C6","volume":"15","author":"A Stoyioglou","year":"2004","unstructured":"Stoyioglou A, Jaff MR . Medical treatment of peripheral arterial disease: A comprehensive review. J Vasc Interv Radiol 2004; 15: 1197\u20131120.","journal-title":"J Vasc Interv Radiol"},{"key":"BFhr2015134_CR10","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/hr.2014.34","volume":"37","author":"S Ichihashi","year":"2014","unstructured":"Ichihashi S, Hashimoto T, Iwakoshi S, Kichikawa K . Validation study of automated oscillometric measurement of the ankle-brachial index for lower arterial occlusive disease by comparison with computed tomography angiography. Hypertens Res 2014; 37: 591\u2013594.","journal-title":"Hypertens Res"},{"key":"BFhr2015134_CR11","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1161\/CIRCULATIONAHA.109.865600","volume":"120","author":"C Diehm","year":"2009","unstructured":"Diehm C, Allenberg JR, Pittrow D, Mahn M, Tepohl G, Haberl RL, Darius H, Burghaus I, Trampisch HJ, German Epidemiological Trial on Ankle Brachial Index Study Group. Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease. Circulation 2009; 120: 2053\u20132061.","journal-title":"Circulation"},{"key":"BFhr2015134_CR12","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s11606-006-5042-4","volume":"12","author":"MM McDermott","year":"1997","unstructured":"McDermott MM, Mehta S, Ahn H, Greenland P . Atherosclerotic risk factors are less intensively treated in patients with peripheral arterial disease than in patients with coronary artery disease. J Gen Intern Med 1997; 12: 209\u2013215.","journal-title":"J Gen Intern Med"},{"key":"BFhr2015134_CR13","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/qjmed\/92.4.219","volume":"92","author":"AL Clark","year":"1999","unstructured":"Clark AL, Byrne JC, Nasser A, McGroarty E, Kennedy JA . Cholesterol in peripheral vascular disease\u2014a suitable case for treatment? QJM 1999; 92: 219\u2013222.","journal-title":"QJM"},{"key":"BFhr2015134_CR14","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1056\/NEJM200105243442108","volume":"344","author":"WR Hiatt","year":"2001","unstructured":"Hiatt WR . Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001; 344: 1608\u20131621.","journal-title":"N Engl J Med"},{"key":"BFhr2015134_CR15","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/jama.286.11.1317","volume":"286","author":"AT Hirsch","year":"2001","unstructured":"Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW, Krook SH, Hunninghake DB, Comerota AJ, Walsh ME, McDermott MM, Hiatt WR . Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001; 286: 1317\u20131324.","journal-title":"JAMA"},{"key":"BFhr2015134_CR16","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.jvs.2012.09.068","volume":"57","author":"MM McDermott","year":"2013","unstructured":"McDermott MM, Kibbe M, Guralnik JM, Pearce WH, Tian L, Liao Y, Zhao L, Criqui MH . Comparative effectiveness study of self-directed walking exercise, lower extremity revascularization, and functional decline in peripheral artery disease. J Vasc Surg 2013; 57: 990\u2013996.","journal-title":"J Vasc Surg"},{"key":"BFhr2015134_CR17","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.2147\/VHRM.S3160","volume":"4","author":"YW Chi","year":"2008","unstructured":"Chi YW, Lavie CJ, Milani RV, White CJ . Safety and efficacy of cilostazol in the management of intermittent claudication. Vasc Health Risk Manag 2008; 4: 1197\u20131203.","journal-title":"Vasc Health Risk Manag"},{"key":"BFhr2015134_CR18","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1161\/CIR.0b013e31828b82aa","volume":"127","author":"JL Anderson","year":"2013","unstructured":"Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Guyton RA, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK . Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF\/AHA guideline recommendations): a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127: 1425\u20131443.","journal-title":"Circulation"},{"key":"BFhr2015134_CR19","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.carrev.2013.08.005","volume":"14","author":"M Lichtenberg","year":"2013","unstructured":"Lichtenberg M, Stahlhoff FW, Boese D . Endovascular treatment of acute limb ischemia and proximal deep vein thrombosis using rotational thrombectomy: a review of published literature. Cardiovasc Revasc Med 2013; 14: 343\u2013348.","journal-title":"Cardiovasc Revasc Med"},{"key":"BFhr2015134_CR20","doi-asserted-by":"crossref","first-page":"658","DOI":"10.2174\/157016111797484107","volume":"9","author":"RA Mangiafico","year":"2011","unstructured":"Mangiafico RA, Mangiafico M . Medical treatment of critical limb ischemia: current state and future directions. Curr Vasc Pharmacol 2011; 9: 658\u2013676.","journal-title":"Curr Vasc Pharmacol"},{"key":"BFhr2015134_CR21","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1097\/01.RVI.0000240426.53079.46","volume":"17","author":"AT Hirsch","year":"2006","unstructured":"Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hiratzka LF, Murphy WR, Olin JW, Puschett JB, Rosenfield KA, Sacks D, Stanley JC, Taylor LM Jr, White CJ, White J, White RA, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B, American Association for Vascular Surgery\/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, ACC\/AHA Task Force on Practice Guidelines. ACC\/AHA guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Associations for Vascular Surgery\/Society for Vascular Surgery. Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC\/AHA Task Force on Practice Guidelines (writing committee to develop guidelines for the management of patients with peripheral arterial disease)\u2014summary of recommendations. J Vasc Interv Radiol 2006; 17: 1383\u20131397.","journal-title":"J Vasc Interv Radiol"},{"key":"BFhr2015134_CR22","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1016\/j.jvs.2011.09.001","volume":"54","author":"TW Rooke","year":"2011","unstructured":"Rooke TW, Hirsch AT, Misra S, Sidawy AN, Beckman JA, Findeiss LK, Golzarian J, Gornik HL, Halperin JL, Jaff MR, Moneta GL, Olin JW, Stanley JC, White CJ, White JV, Zierler RE, American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society for Vascular Medicine, Society for Vascular Surgery. 2011 ACCF\/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation\/ American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society for Vascular Medicine, and Society for Vascular Surgery. J Vasc Surg 2011; 54: e32\u2013e58.","journal-title":"J Vasc Surg"},{"key":"BFhr2015134_CR23","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0741-5214(03)00129-0","volume":"38","author":"K Cassar","year":"2003","unstructured":"Cassar K, Bachoo P, Ford I, Greaves M, Brittenden J . Platelet activation is increased in peripheral arterial disease. J Vasc Surg 2003; 38: 99\u2013103.","journal-title":"J Vasc Surg"},{"key":"BFhr2015134_CR24","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","volume":"373","author":"C Baigent","year":"2009","unstructured":"Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A . Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849\u20131860.","journal-title":"Lancet"},{"key":"BFhr2015134_CR25","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","volume":"324","author":"Antithrombotic Trialists\u2019 Collaboration","year":"2002","unstructured":"Antithrombotic Trialists\u2019 Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71\u201386.","journal-title":"BMJ"},{"key":"BFhr2015134_CR26","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1001\/jama.2009.623","volume":"301","author":"JS Berger","year":"2009","unstructured":"Berger JS, Krantz MJ, Kittelson JM, Hiatt WR . Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA 2009; 301: 1909\u20131919.","journal-title":"JAMA"},{"key":"BFhr2015134_CR27","doi-asserted-by":"crossref","first-page":"a1840","DOI":"10.1136\/bmj.a1840","volume":"337","author":"J Belch","year":"2008","unstructured":"Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, Lee R, Bancroft J, MacEwan S, Shepherd J, Macfarlane P, Morris A, Jung R, Kelly C, Connacher A, Peden N, Jamieson A, Matthews D, Leese G, McKnight J, O'Brien I, Semple C, Petrie J, Gordon D, Pringle S, MacWalter R, Prevention of Progression of Arterial Disease and Diabetes Study Group, Diabetes Registry Group, Royal College of Physicians Edinburgh. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomized placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008; 337: a1840\u2013a1849.","journal-title":"BMJ"},{"key":"BFhr2015134_CR28","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/jama.2010.221","volume":"303","author":"FG Fowkes","year":"2010","unstructured":"Fowkes FG, Price JF, Stewart MC, Butcher I, Leng GC, Pell AC, Sandercock PA, Fox KA, Lowe GD, Murray GD, Aspirin for Asymptomatic Atherosclerosis Trialists. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 2010; 303: 841\u2013848.","journal-title":"JAMA"},{"key":"BFhr2015134_CR29","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","volume":"348","author":"CAPRIE Steering Committee","year":"1996","unstructured":"CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329\u20131339.","journal-title":"Lancet"},{"key":"BFhr2015134_CR30","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.jvs.2010.04.027","volume":"52","author":"JJ Belch","year":"2010","unstructured":"Belch JJ, Dormandy J, CASPAR Writing Committee. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. J Vasc Surg 2010; 52: 825\u2013833.","journal-title":"J Vasc Surg"},{"key":"BFhr2015134_CR31","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/eurheartj\/ehn534","volume":"30","author":"PP Cacoub","year":"2009","unstructured":"Cacoub PP, Bhatt DL, Steg PG, Topol EJ, Creager MA, CHARISMA Investigators. Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J 2009; 30: 192\u2013201.","journal-title":"Eur Heart J"},{"key":"BFhr2015134_CR32","doi-asserted-by":"crossref","unstructured":"The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res 2014; 37: 253\u2013390.","DOI":"10.1038\/hr.2014.20"},{"key":"BFhr2015134_CR33","doi-asserted-by":"crossref","first-page":"e0135692","DOI":"10.1371\/journal.pone.0135692","volume":"10","author":"K Katsanos","year":"2015","unstructured":"Katsanos K, Spiliopoulos S, Saha P, Diamantopoulos A, Karunanithy N, Krokidis M, Modarai B, Karnabatidis D . Comparative efficacy and safety of different antiplatelet agents for prevention of major cardiovascular events and leg amputations in patients with peripheral arterial disease: a systematic review and network meta-analysis. PLoS ONE 2015; 10: e0135692.","journal-title":"PLoS ONE"},{"key":"BFhr2015134_CR34","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa065959","volume":"357","author":"S Anand","year":"2007","unstructured":"Warfarin Antiplatelet Vascular Evaluation Trial Investigators, Anand S, Yusuf S, Xie C, Pogue J, Eikelboom J, Budaj A, Sussex B, Liu L, Guzman R, Cina C, Crowell R, Keltai M, Gosselin G . Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 2007; 357: 217\u2013227.","journal-title":"N Engl J Med"},{"key":"BFhr2015134_CR35","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","volume":"342","author":"S Yusuf","year":"2000","unstructured":"Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G . Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145\u2013153.","journal-title":"N Engl J Med"},{"key":"BFhr2015134_CR36","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jacc.2014.12.043","volume":"65","author":"TP Murphy","year":"2015","unstructured":"Murphy TP, Cutlip DE, Regensteiner JG, Mohler ER 3rd, Cohen DJ, Reynolds MR, Massaro JM, Lewis BA, Cerezo J, Oldenburg NC, Thum CC, Jaff MR, Comerota AJ, Steffes MW, Abrahamsen IH, Goldberg S, Hirsch AT . Supervised exercise, stent revascularization, or medical therapy for claudication due to aortoiliac peripheral artery disease: the CLEVER study. J Am Coll Cardiol 2015; 65: 999\u20131009.","journal-title":"J Am Coll Cardiol"},{"key":"BFhr2015134_CR37","first-page":"287","volume":"25","author":"H Tsuchida","year":"2006","unstructured":"Tsuchida H, Shigematsu H, Ishimaru S, Iwai T, Akaba N, Umezu S . Effect of low-density lipoprotein apheresis on patients with peripheral arterial disease. Peripheral Arterial Disease LDL Apheresis Multicenter Study (P-LAS). Int Angiol 2006; 25: 287\u2013292.","journal-title":"Int Angiol"},{"key":"BFhr2015134_CR38","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/ccd.26122","volume":"86","author":"MR Jaff","year":"2015","unstructured":"Jaff MR, White CJ, Hiatt WR, Fowkes GR, Dormandy J, Razavi M, Reekers J, Norgren L . An update on methods for revascularization and expansion of the TASC lesion classification to include below-the-knee arteries: a supplement to the inter-society consensus for the management of peripheral arterial disease (TASC II): The TASC steering committee. Catheter Cardiovasc Interv 2015; 86: 611\u2013625.","journal-title":"Catheter Cardiovasc Interv"},{"key":"BFhr2015134_CR39","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jcin.2014.09.009","volume":"8","author":"EJ Dippel","year":"2015","unstructured":"Dippel EJ, Makam P, Kovach R, George JC, Patlola R, Metzger DC, Mena-Hurtado C, Beasley R, Soukas P, Colon-Hernandez PJ, Stark MA, Walker C, EXCITE ISR Investigators. Randomized controlled study of excimer laser atherectomy for treatment of femoropopliteal in-stent restenosis: initial results from the EXCITE ISR trial (EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis). JACC Cardiovasc Interv 2015; 8: 92\u2013101.","journal-title":"JACC Cardiovasc Interv"},{"key":"BFhr2015134_CR40","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jvs.2008.03.042","volume":"48","author":"RW Chang","year":"2008","unstructured":"Chang RW, Goodney PP, Baek JH, Nolan BW, Rzucidlo EM, Powell RJ . Long-term results of combined common femoral endarterectomy and iliac stenting\/stent grafting for occlusive disease. J Vasc Surg 2008; 48: 362\u2013367.","journal-title":"J Vasc Surg"},{"key":"BFhr2015134_CR41","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s40265-014-0252-2","volume":"74","author":"RM Poole","year":"2014","unstructured":"Poole RM, Elkinson S . Vorapaxar: first global approval. Drugs 2014; 74: 1153\u20131163.","journal-title":"Drugs"},{"key":"BFhr2015134_CR42","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1161\/CIRCULATIONAHA.112.000679","volume":"127","author":"MP Bonaca","year":"2013","unstructured":"Bonaca MP, Scirica BM, Creager MA, Olin J, Bounameaux H, Dellborg M, Lamp JM, Murphy SA, Braunwald E, Morrow DA . Vorapaxar in patients with peripheral artery disease: results from TRA2 P-TIMI 50. Circulation 2013; 127: 1522\u20131529 1529e1-6.","journal-title":"Circulation"},{"key":"BFhr2015134_CR43","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.ahj.2014.06.017","volume":"168","author":"WS Jones","year":"2014","unstructured":"Jones WS, Tricoci P, Huang Z, Moliterno DJ, Harrington RA, Sinnaeve PR, Strony J, Van de Werf F, White HD, Held C, Armstrong PW, Aylward PE, Chen E, Patel MR, Mahaffey KW . Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER). Am Heart J 2014; 168: 588\u2013596.","journal-title":"Am Heart J"},{"key":"BFhr2015134_CR44","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/CRD.0000000000000075","volume":"23","author":"S Lam","year":"2015","unstructured":"Lam S, Tran T . Vorapaxar: a protease-activated receptor antagonist for the prevention of thrombotic events. Cardiol Rev 2015; 23: 261\u2013267.","journal-title":"Cardiol Rev"},{"key":"BFhr2015134_CR45","doi-asserted-by":"crossref","first-page":"71B","DOI":"10.1016\/0002-9149(95)80017-M","volume":"75","author":"TJ Anderson","year":"1995","unstructured":"Anderson TJ, Gerhard MD, Meredith IT, Charbonneau F, Delagrange D, Creager MA, Selwyn AP, Ganz P . Systemic nature of endothelial dysfunction in atherosclerosis. Am J Cardiol 1995; 75: 71B\u201374B.","journal-title":"Am J Cardiol"},{"key":"BFhr2015134_CR46","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1161\/01.RES.68.4.1027","volume":"68","author":"JK Liao","year":"1991","unstructured":"Liao JK, Bettmann MA, Sandor T, Tucker JI, Coleman SM, Creager MA . Differential impairment of vasodilator responsiveness of peripheral resistance and conduit vessels in humans with atherosclerosis. Circ Res 1991; 68: 1027\u20131034.","journal-title":"Circ Res"},{"key":"BFhr2015134_CR47","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1113\/jphysiol.2002.021477","volume":"543","author":"R Boushel","year":"2002","unstructured":"Boushel R, Langberg H, Gemmer C, Olesen J, Crameri R, Scheede C, Sander M, Kjaer M . Combined inhibition of nitric oxide and prostaglandins reduces human skeletal muscle blood flow during exercise. J Physiol 2002; 543: 691\u2013698.","journal-title":"J Physiol"},{"key":"BFhr2015134_CR48","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1345\/aph.19408","volume":"35","author":"MP Reilly","year":"2001","unstructured":"Reilly MP, Mohler ER III . Cilostazol: treatment of intermittent claudication. Ann Pharmacother 2001; 35: 48\u201356.","journal-title":"Ann Pharmacother"},{"key":"BFhr2015134_CR49","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/S0002-9149(02)02869-2","volume":"90","author":"PD Thompson","year":"2002","unstructured":"Thompson PD, Zimet R, Forbes WP, Zhang P . Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol 2002; 90: 1314\u20131319.","journal-title":"Am J Cardiol"},{"key":"BFhr2015134_CR50","first-page":"1053","volume":"155","author":"SC Hood","year":"1996","unstructured":"Hood SC, Moher D, Barber GG . Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials. CMAJ 1996; 155: 1053\u20131059.","journal-title":"CMAJ"},{"key":"BFhr2015134_CR51","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1002\/bjs.8895","volume":"99","author":"JW Stevens","year":"2012","unstructured":"Stevens JW, Simpson E, Harnan S, Squires H, Meng Y, Thomas S, Michaels J, Stansby G . Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. Br J Surg 2012; 99: 1630\u20131638.","journal-title":"Br J Surg"},{"key":"BFhr2015134_CR52","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2165\/00002512-199608040-00005","volume":"8","author":"LB Barradell","year":"1996","unstructured":"Barradell LB, Brogden RN . Oral naftidrofuryl. A review of its pharmacology and therapeutic use in the management of peripheral occlusive arterial disease. Drugs Aging 1996; 8: 299\u2013322.","journal-title":"Drugs Aging"},{"key":"BFhr2015134_CR53","doi-asserted-by":"crossref","first-page":"b603","DOI":"10.1136\/bmj.b603","volume":"338","author":"T De Backer","year":"2009","unstructured":"De Backer T, Vander Stichele R, Lehert P, Van Bortel L . Naftidrofuryl for intermittent claudication: meta-analysis based on individual patient data. BMJ 2009; 338: b603\u2013b610.","journal-title":"BMJ"},{"key":"BFhr2015134_CR54","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1042\/cs0930159","volume":"93","author":"SM Schellong","year":"1997","unstructured":"Schellong SM, Boger RH, Burchert W, Bode-B\u00f6ger SM, Galland A, Fr\u00f6lich JC, Hundeshagen H, Alexander K . Dose-related effect of intravenous L-arginine on muscular blood flow of the calf in patients with peripheral vascular disease: a H215O positron emission tomography study. Clin Sci (Lond) 1997; 93: 159\u2013165.","journal-title":"Clin Sci (Lond)"},{"key":"BFhr2015134_CR55","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1161\/01.CIR.95.9.2298","volume":"95","author":"JJ Belch","year":"1997","unstructured":"Belch JJ, Bell PR, Creissen D, Dormandy JA, Kester RC, McCollum RD, Mizushima Y, Ruckley CV, Scurr JH, Wolfe JH . Randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of AS-013, a prostaglandin E1 prodrug, in patients with intermittent claudication. Circulation 1997; 95: 2298\u20132302.","journal-title":"Circulation"},{"key":"BFhr2015134_CR56","first-page":"CD006544","volume":"1","author":"AJ Ruffolo","year":"2010","unstructured":"Ruffolo AJ, Romano M, Ciapponi A . Prostanoids for critical limb ischaemia. Cochrane Database Syst Rev 2010; 1: CD006544.","journal-title":"Cochrane Database Syst Rev"},{"key":"BFhr2015134_CR57","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1097\/00005344-199606000-00004","volume":"27","author":"M Lievre","year":"1996","unstructured":"Lievre M, Azoulay S, Lion L, Morand S, Girre JP, Boissel JP . A dose\u2013effect study of beraprost sodium in intermittent claudication. J Cardiovasc Pharmacol 1996; 27: 788\u2013793.","journal-title":"J Cardiovasc Pharmacol"},{"key":"BFhr2015134_CR58","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1161\/01.CIR.102.4.426","volume":"102","author":"M Lievre","year":"2000","unstructured":"Lievre M, Morand S, Besse B, Fiessinger JN, Boissel JP . Oral Beraprost sodium, a prostaglandin I(2) analogue, for intermittent claudication: a double-blind, randomized, multicenter controlled trial. Beraprost et Claudication Intermittente (BERCI) Research Group. Circulation 2000; 102: 426\u2013431.","journal-title":"Circulation"},{"key":"BFhr2015134_CR59","first-page":"60243","volume":"S0140-6736","author":"JL Mega","year":"2015","unstructured":"Mega JL, Simon T . Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments. Lancet 2015; S0140-6736: 60243\u201360244.","journal-title":"Lancet"},{"key":"BFhr2015134_CR60","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","volume":"357","author":"SD Wiviott","year":"2007","unstructured":"Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM, TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001\u20132015.","journal-title":"N Engl J Med"},{"key":"BFhr2015134_CR61","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, PLATO Investigators Freij A, Thors\u00e9n M . Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045\u20131057.","journal-title":"N Engl J Med"},{"key":"BFhr2015134_CR62","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","volume":"383","author":"CT Ruff","year":"2014","unstructured":"Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM . Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955\u2013962.","journal-title":"Lancet"},{"key":"BFhr2015134_CR63","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S0140-6736(96)03361-2","volume":"348","author":"JM Isner","year":"1996","unstructured":"Isner JM, Pieczek A, Schainfeld R, Blair R, Haley L, Asahara T, Rosenfield K, Razvi S, Walsh K, Symes JF . Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 1996; 348: 370\u2013374.","journal-title":"Lancet"},{"key":"BFhr2015134_CR64","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1161\/01.CIR.97.12.1114","volume":"97","author":"I Baumgartner","year":"1998","unstructured":"Baumgartner I, Pieczek A, Manor O, Blair R, Kearney M, Walsh K, Isner JM . Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998; 97: 1114\u20131123.","journal-title":"Circulation"},{"key":"BFhr2015134_CR65","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/S0741-5214(98)70022-9","volume":"28","author":"JM Isner","year":"1998","unstructured":"Isner JM, Baumgartner I, Rauhetal G . Treatment of thromboangiitis obliterans (Buerger\u2019s disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results. J Vasc Surg 1998; 28: 964\u2013975.","journal-title":"J Vasc Surg"},{"key":"BFhr2015134_CR66","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1006\/mthe.2002.0638","volume":"6","author":"K M\u00e4kinen","year":"2002","unstructured":"M\u00e4kinen K, Mannine H, Hedman M, Matsi P, Mussalo H, Alhava E, Yl\u00e4-Herttuala S . Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study. Mol Ther 2002; 6: 127\u2013133.","journal-title":"Mol Ther"},{"key":"BFhr2015134_CR67","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1161\/hc3201.095192","volume":"104","author":"S Rajagopalan","year":"2001","unstructured":"Rajagopalan S, Shah M, Luciano A, Crystal R, Nabel EG . Adenovirus-mediated gene transfer of VEGF121 improves lower-extremity endothelial function and flow reserve. Circulation 2001; 104: 753\u2013755.","journal-title":"Circulation"},{"key":"BFhr2015134_CR68","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1089\/hum.2006.17.683","volume":"17","author":"YH Kusumanto","year":"2006","unstructured":"Kusumanto YH, van Weel V, Mulder NH, Smit AJ, van den Dungen JJ, Hooymans JM, Sluiter WJ, Tio RA, Quax PH, Gans RO, Dullaart RP, Hospers GA . Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial. Hum Gene Ther 2006; 17: 683\u2013691.","journal-title":"Hum Gene Ther"},{"key":"BFhr2015134_CR69","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1161\/01.CIR.0000093398.16124.29","volume":"108","author":"S Rajagopalan","year":"2003","unstructured":"Rajagopalan S, Mohler ER 3rd, Ledermanetal RJ . Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 2003; 108: 1933\u20131938.","journal-title":"Circulation"},{"key":"BFhr2015134_CR70","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/gt.2011.109","volume":"19","author":"K Muona","year":"2012","unstructured":"Muona K, Makinen K, Hedman M, Manninen H, Yl\u00e4-Herttuala S . 10-Year safety follow-up in patients with local VEGF gene transfer to ischemic lower limb. Gene Ther 2012; 19: 392\u2013395.","journal-title":"Gene Ther"},{"key":"BFhr2015134_CR71","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1067\/mva.2002.123677","volume":"35","author":"AJ Comerota","year":"2002","unstructured":"Comerota AJ, Throm RC, Miller KA, Henry T, Chronos N, Laird J, Sequeira R, Kent CK, Bacchetta M, Goldman C, Salenius JP, Schmieder FA, Pilsudski R . Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a phase I trial. J Vasc Surg 2002; 35: 930\u2013936.","journal-title":"J Vasc Surg"},{"key":"BFhr2015134_CR72","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1038\/mt.2008.33","volume":"16","author":"S Nikol","year":"2008","unstructured":"Nikol S, Baumgartner I, van Belle E, Diehm C, Vison\u00e1 A, Capogrossi MC, Ferreira-Maldent N, Gallino A, Wyatt MG, Wijesinghe LD, Fusari M, Stephan D, Emmerich J, Pompilio G, Vermassen F, Pham E, Grek V, Coleman M, Meyer F, TALISMAN 201 investigators. Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Mol Ther 2008; 16: 972\u2013978.","journal-title":"Mol Ther"},{"key":"BFhr2015134_CR73","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(11)60394-2","volume":"377","author":"J Belch","year":"2011","unstructured":"Belch J, Hiatt WR, Baumgartner I, Driver IV, Nikol S, Norgren L, Van Belle E, TAMARIS Committees and Investigators. Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia. Lancet 2011; 377: 1929\u20131937.","journal-title":"Lancet"},{"key":"BFhr2015134_CR74","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.vph.2012.02.002","volume":"57","author":"T Kaga","year":"2012","unstructured":"Kaga T, Kawano H, Sakaguchi M, Nakazawa T, Taniyama Y, Morishita R . Hepatocyte growth factor stimulated angiogenesis without inflammation: differential actions between hepatocyte growth factor, vascular endothelial growth factor and basic fibroblast growth factor. Vasc Pharmacol 2012; 57: 3\u20139.","journal-title":"Vasc Pharmacol"},{"key":"BFhr2015134_CR75","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1161\/01.HYP.33.6.1379","volume":"33","author":"R Morishita","year":"1999","unstructured":"Morishita R, Nakamura S, Hayashi S, Taniyama Y, Moriguchi A, Nagano T, Taiji M, Noguchi H, Takeshita S, Matsumoto K, Nakamura T, Higaki J, Ogihara T . Therapeutic angiogenesis induced by human recombinant hepatocyte growth factor in rabbit hind limb ischemia model as cytokine supplement therapy. Hypertension 1999; 33: 1379\u20131384.","journal-title":"Hypertension"},{"key":"BFhr2015134_CR76","doi-asserted-by":"crossref","first-page":"II301","DOI":"10.1161\/01.CIR.100.suppl_2.II-301","volume":"100","author":"S Hayashi","year":"1999","unstructured":"Hayashi S, Morishita R, Nakamura S, Yamamoto K, Moriguchi A, Nagano T, Taiji M, Noguchi H, Matsumoto K, Nakamura T, Higaki J, Ogihara T . Potential role of hepatocyte growth factor, a novel angiogenic growth factor, in peripheral arterial disease: downregulation of HGF in response to hypoxia in vascular cells. Circulation 1999; 100: II301\u2013II308.","journal-title":"Circulation"},{"key":"BFhr2015134_CR77","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1161\/01.CIR.0000093275.78676.F4","volume":"108","author":"K Hiraoka","year":"2003","unstructured":"Hiraoka K, Koike H, Yamamoto S, Tomita N, Yokoyama C, Tanabe T, Aikou T, Ogihara T, Kaneda Y, Morishita R . Enhanced therapeutic angiogenesis by cotransfection of prostacyclin synthase gene or optimization of intramuscular injection of naked plasmid DNA. Circulation 2003; 108: 2689\u20132696.","journal-title":"Circulation"},{"key":"BFhr2015134_CR78","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1096\/fj.02-0754fje","volume":"17","author":"H Koike","year":"2003","unstructured":"Koike H, Morishita R, Iguchi S, Aoki M, Matsumoto K, Nakamura T, Yokoyama C, Tanabe T, Ogihara T, Kaneda Y . Enhanced angiogenesis and improvement of neuropathy by cotransfection of human hepatocyte growth factor and prostacyclin synthase gene. FASEB J 2003; 17: 779\u2013781.","journal-title":"FASEB J"},{"key":"BFhr2015134_CR79","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1161\/hc4401.098470","volume":"104","author":"Y Taniyama","year":"2001","unstructured":"Taniyama Y, Morishita R, Hiraoka K, Aoki M, Nakagami H, Yamasaki K, Matsumoto K, Nakamura T, Kaneda Y, Ogihara T . Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat diabetic hind limb ischemia model: molecular mechanisms of delayed angiogenesis in diabetes. Circulation 2001; 104: 2344\u20132350.","journal-title":"Circulation"},{"key":"BFhr2015134_CR80","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/sj.gt.3301379","volume":"8","author":"Y Taniyama","year":"2001","unstructured":"Taniyama Y, Morishita R, Aoki M, Nakagami H, Yamamoto K, Yamazaki K, Matsumoto K, Nakamura T, Kaneda Y, Ogihara T . Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat and rabbit hindlimb ischemia models: preclinical study for treatment of peripheral arterial disease. Gene Ther 2001; 8: 181\u2013189.","journal-title":"Gene Ther"},{"key":"BFhr2015134_CR81","doi-asserted-by":"crossref","first-page":"10024","DOI":"10.1016\/S0021-9258(18)82167-6","volume":"268","author":"K Miyazawa","year":"1993","unstructured":"Miyazawa K, Shimomura T, Kitamura A, Kondo J, Morimoto Y, Kitamura N . Molecular cloning and sequence analysis of the cDNA for a human serine protease responsible for activation of hepatocyte growth factor. Structural similarity of the protease precursor to blood coagulation factor XII. J Biol Chem 1993; 268: 10024\u201310028.","journal-title":"J Biol Chem"},{"key":"BFhr2015134_CR82","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1161\/ATVBAHA.110.219550","volume":"31","author":"R Morishita","year":"2011","unstructured":"Morishita R, Makino H, Aoki M, Hashiya N, Yamasaki K, Azuma J, Taniyama Y, Sawa Y, Kaneda Y, Ogihara T . Phase I\/IIa clinical trial of therapeutic angiogenesis using hepatocyte growth factor gene transfer to treat critical limb ischemia. Arterioscler Thromb Vasc Biol 2011; 31: 713\u2013720.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"BFhr2015134_CR83","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1161\/ATVBAHA.111.244632","volume":"32","author":"H Makino","year":"2012","unstructured":"Makino H, Aoki M, Hashiya N, Yamasaki K, Azuma J, Sawa Y, Kaneda Y, Ogihara T, Morishita R . Long-term follow-up evaluation of results from clinical trial using hepatocyte growth factor gene to treat severe peripheral arterial disease. Arterioscler Thromb Vasc Biol 2012; 32: 2503\u20132509.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"BFhr2015134_CR84","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1161\/CIRCULATIONAHA.107.727347","volume":"118","author":"RJ Powell","year":"2008","unstructured":"Powell RJ, Simons M, Mendelsohn FO, Daniel G, Henry TD, Koga M, Morishita R, Annex BH . Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation 2008; 118: 58\u201365.","journal-title":"Circulation"},{"key":"BFhr2015134_CR85","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.jvs.2010.07.044","volume":"52","author":"RJ Powell","year":"2010","unstructured":"Powell RJ, Goodney P, Mendelsohn FO, Moen EK, Annex BH, HGF-0205 Trial Investigators. Safety and efficacy of patient specific intramuscular injection of HGF plasmid gene therapy on limb perfusion and wound healing in patients with ischemic lower extremity ulceration: results of the HGF-0205 trial. J Vasc Surg 2010; 52: 1525\u20131530.","journal-title":"J Vasc Surg"},{"key":"BFhr2015134_CR86","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/gt.2010.51","volume":"17","author":"H Shigematsu","year":"2010","unstructured":"Shigematsu H, Yasuda K, Iwai T, Sasajima T, Ishimaru S, Ohashi Y, Yamaguchi T, Ogihara T, Morishita R . Randomized, double- blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia. Gene Ther 2010; 17: 1152\u20131161.","journal-title":"Gene Ther"},{"key":"BFhr2015134_CR87","first-page":"140","volume":"30","author":"H Shigematsu","year":"2011","unstructured":"Shigematsu H, Yasuda K, Sasajima T, Takano T, Miyata T, Ohta T, Tanemoto K, Obitsu Y, Iwai T, Ozaki S, Ogihara T, Morishita R,, HGF Study Group. Transfection of human HGF plasmid DNA improves limb salvage in Buerger\u2019s disease patient with critical limb ischemia. Int Angiol 2011; 30: 140\u2013149.","journal-title":"Int Angiol"},{"key":"BFhr2015134_CR88","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1126\/science.275.5302.964","volume":"275","author":"T Asahara","year":"1997","unstructured":"Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM . Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275: 964\u2013967.","journal-title":"Science"},{"key":"BFhr2015134_CR89","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1002\/stem.207","volume":"27","author":"A Kawamoto","year":"2009","unstructured":"Kawamoto A, Katayama M, Handa N, Kinoshita M, Takano H, Horii M, Sadamoto K, Yokoyama A, Yamanaka T, Onodera R, Kuroda A, Baba R, Kaneko Y, Tsukie T, Kurimoto Y, Okada Y, Kihara Y, Morioka S, Fukushima M, Asahara T . Intramuscular transplantation of G-CSF-mobilized CD34+ cells in patients with critical limb ischemia: a phase I\/IIa, multicenter, single- blinded, dose-escalation clinical trial. Stem Cells 2009; 27: 2857\u20132864.","journal-title":"Stem Cells"},{"key":"BFhr2015134_CR90","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.atherosclerosis.2012.07.031","volume":"224","author":"M Kinoshita","year":"2012","unstructured":"Kinoshita M, Fujita Y, Katayama M, Baba R, Shibakawa M, Yoshikawa K, Katakami N, Furukawa Y, Tsukie T, Nagano T, Kurimoto Y, Yamasaki K, Handa N, Okada Y, Kuronaka K, Nagata Y, Matsubara Y, Fukushima M, Asahara T, Kawamoto A . Long-term clinical outcome after intramuscular transplantation of granulocyte colony stimulating factor-mobilized CD34 positive cells in patients with critical limb ischemia. Atherosclerosis 2012; 224: 440\u2013445.","journal-title":"Atherosclerosis"},{"key":"BFhr2015134_CR91","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0140-6736(02)09670-8","volume":"360","author":"E Tateishi-Yuyama","year":"2002","unstructured":"Tateishi-Yuyama E, Matsubara H, Murohara T, Ikeda U, Shintani S, Masaki H, Amano K, Kishimoto Y, Yoshimoto K, Akashi H, Shimada K, Iwasaka T, Imaizumi T, Therapeutic Angiogenesis using Cell Transplantation (TACT) Study Investigators. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bonemarrow cells: a pilot study and a randomised controlled trial. Lancet 2002; 360: 427\u2013435.","journal-title":"Lancet"},{"key":"BFhr2015134_CR92","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.ahj.2008.06.025","volume":"156","author":"S Matoba","year":"2008","unstructured":"Matoba S, Tatsumi T, Murohara T, Imaizumi T, Katsuda Y, Ito M, Saito Y, Uemura S, Suzuki H, Fukumoto S, Yamamoto Y, Onodera R, Teramukai S, Fukushima M, Matsubara H,, TACT Follow-up Study Investigators. Long-term clinical outcome after intramuscular implantation of bone marrow mononuclear cells (therapeutic angiogenesis by cell transplantation [TACT] trial) in patients with chronic limb ischemia. Am Heart J 2008; 156: 1010\u20131018.","journal-title":"Am Heart J"},{"key":"BFhr2015134_CR93","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1161\/CIRCINTERVENTIONS.110.958348","volume":"4","author":"DH Walter","year":"2011","unstructured":"Walter DH, Krankenberg H, Balzer JO, Kalka C, Baumgartner I, Schl\u00fcter M, Tonn T, Seeger F, Dimmeler S, Lindhoff-Last E, Zeiher AM,, PROVASA Investigators. Intraarterial administration of bone marrow mononuclear cells in patients with critical limb ischemia a randomized-start, placebo-controlled pilot trial (PROVASA). Circ Cardiovasc Interv 2011; 4: 26\u201337.","journal-title":"Circ Cardiovasc Interv"},{"key":"BFhr2015134_CR94","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1161\/01.RES.0000219901.13974.15","volume":"98","author":"K Tateno","year":"2006","unstructured":"Tateno K, Minamino T, Tokoetal H . Critical roles of muscle-secreted angiogenic factors in therapeutic neovascularization. Circ Res 2006; 98: 1194\u20131202.","journal-title":"Circ Res"},{"key":"BFhr2015134_CR95","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1161\/CIRCINTERVENTIONS.108.799361","volume":"2","author":"J Moriya","year":"2009","unstructured":"Moriya J, Minamino T, Tateno K, Shimizu N, Kuwabara Y, Sato Y, Saito Y, Komuro I . Long-term outcome of therapeutic neovascularization using peripheral blood mononuclear cells for limb ischemia. Circ Cardiovasc Interv 2009; 2: 245\u2013254.","journal-title":"Circ Cardiovasc Interv"},{"key":"BFhr2015134_CR96","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s10047-006-0351-2","volume":"9","author":"A Kawamura","year":"2006","unstructured":"Kawamura A, Horie T, Tsuda I, Abe Y, Yamada M, Egawa H, Iida J, Sakata H, Onodera K, Tamaki T, Furui H, Kukita K, Meguro J, Yonekawa M, Tanaka S . Clinical study of therapeutic angiogenesis by autologous peripheral blood stem cell (PBSC) transplantation in 92 patients with critically ischemic limbs. J Artif Organs 2006; 9: 226\u2013233.","journal-title":"J Artif Organs"},{"key":"BFhr2015134_CR97","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/bmt.2010.110","volume":"46","author":"R Onodera","year":"2011","unstructured":"Onodera R, Teramukai S, Tanaka S, Kojima S, Horie T, Matoba S, Murohara T, Matsubara H, Fukushima M, BMMNC Follow-Up Study Investigators, M-PBMNC Follow-Up Study Investigators. Bone marrow mononuclear cells versus G-CSF-mobilized peripheral blood mononuclear cells for treatment of lower limb ASO: pooled analysis for long-term prognosis. Bone Marrow Transplant 2011; 46: 278\u2013284.","journal-title":"Bone Marrow Transplant"},{"key":"BFhr2015134_CR98","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.atherosclerosis.2009.07.050","volume":"208","author":"T Horie","year":"2010","unstructured":"Horie T, Onodera R, Akamastu M, Ichikawa Y, Hoshino J, Kaneko E, Iwashita C, Ishida A, Tsukamoto T, Teramukai S, Fukushima M, Kawamura A, Japan Study Group of Peripheral Vascular Regeneration Cell Therapy (JPRCT). Long-term clinical outcomes for patients with lower limb ischemia implanted with G-CSF-mobilized autologous peripheral blood mononuclear cells. Atherosclerosis 2010; 208: 461\u2013466.","journal-title":"Atherosclerosis"},{"key":"BFhr2015134_CR99","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.bbrc.2007.01.045","volume":"354","author":"Y Iso","year":"2007","unstructured":"Iso Y, Spees JL, Serrano C, Bakondi B, Pochampally R, Song YH, Sobel BE, Delafontaine P, Prockop DJ . Multipotent human stromal cells improve cardiac function after myocardial infarction in mice without long-term engraftment. Biochem Biophys Res Commun 2007; 354: 700\u2013706.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFhr2015134_CR100","doi-asserted-by":"crossref","first-page":"11474","DOI":"10.1073\/pnas.0504388102","volume":"102","author":"LC Amado","year":"2005","unstructured":"Amado LC, Saliaris AP, Schuleri KH, St John M, Xie JS, Cattaneo S, Durand DJ, Fitton T, Kuang JQ, Stewart G, Lehrke S, Baumgartner WW, Martin BJ, Heldman AW, Hare JM . Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. Proc Natl Acad Sci USA 2005; 102: 11474\u201311479.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFhr2015134_CR101","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.cardiores.2006.02.016","volume":"70","author":"SY Lim","year":"2006","unstructured":"Lim SY, Kim YS, Ahn Y, Jeong MH, Hong MH, Joo SY, Nam KI, Cho JG, Kang PM, Park JC . The effects of mesenchymal stem cells transduced with Akt in a porcine myocardial infarction model. Cardiovasc Res 2006; 70: 530\u2013542.","journal-title":"Cardiovasc Res"},{"key":"BFhr2015134_CR102","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.cardiores.2005.02.006","volume":"66","author":"T Iwase","year":"2005","unstructured":"Iwase T, Nagaya N, Fujii T, Itoh T, Murakami S, Matsumoto T, Kangawa K, Kitamura S . Comparison of angiogenic potency between mesenchymal stem cells and mononuclear cells in a rat model of hindlimb ischemia. Cardiovasc Res 2005; 66: 543\u2013551.","journal-title":"Cardiovasc Res"},{"key":"BFhr2015134_CR103","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1634\/stemcells.2008-0236","volume":"26","author":"S Ishikane","year":"2008","unstructured":"Ishikane S, Ohnishi S, Yamahara K, Sada M, Harada K, Mishima K, Iwasaki K, Fujiwara M, Kitamura S, Nagaya N, Ikeda T . Allogeneic injection of fetal membrane-derived mesenchymal stem cells induces therapeutic angiogenesis in a rat model of hind limb ischemia. Stem Cells 2008; 26: 2625\u20132633.","journal-title":"Stem Cells"},{"key":"BFhr2015134_CR104","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.diabres.2010.12.010","volume":"92","author":"D Lu","year":"2011","unstructured":"Lu D, Chen B, Liang Z, Deng W, Jiang Y, Li S, Xu J, Wu Q, Zhang Z, Xie B, Chen S . Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double-blind, randomized, controlled trial. Diabetes Res Clin Pract 2011; 92: 26\u201336.","journal-title":"Diabetes Res Clin Pract"},{"key":"BFhr2015134_CR105","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1182\/blood-2002-06-1877","volume":"101","author":"T Yurugi-Kobayashi","year":"2003","unstructured":"Yurugi-Kobayashi T, Itoh H, Yamashita J, Yamahara K, Hirai H, Kobayashi T, Ogawa M, Nishikawa S, Nishikawa S, Nakao K . Effective contribution of transplanted vascular progenitor cells derived from embryonic stem cells to adult neovascularization in proper differentiation stage. Blood 2003; 101: 2675\u20132678.","journal-title":"Blood"},{"key":"BFhr2015134_CR106","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.cell.2006.07.024","volume":"126","author":"K Takahashi","year":"2006","unstructured":"Takahashi K, Yamanaka S . Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 663\u2013676.","journal-title":"Cell"},{"key":"BFhr2015134_CR107","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1161\/CIRCULATIONAHA.108.769562","volume":"118","author":"G Narazaki","year":"2008","unstructured":"Narazaki G, Uosaki H, Teranishi M, Okita K, Kim B, Matsuoka S, Yamanaka S, Yamashita JK . Directed and systematic differentiation of cardiovascular cells from mouse induced pluripotent stem cells. Circulation 2008; 118: 498\u2013506.","journal-title":"Circulation"},{"key":"BFhr2015134_CR108","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1471-2121-11-72","volume":"11","author":"H Suzuki","year":"2010","unstructured":"Suzuki H, Shibata R, Kito T, Ishii M, Li P, Yoshikai T, Nishio N, Ito S, Numaguchi Y, Yamashita JK, Murohara T, Isobe K . Therapeutic angiogenesis by transplantation of induced pluripotent stem cell-derived Flk-1 positive cells. BMC Cell Biol 2010; 11: 72.","journal-title":"BMC Cell Biol"},{"key":"BFhr2015134_CR109","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1097\/SLA.0b013e3182854cf1","volume":"258","author":"M Teraa","year":"2013","unstructured":"Teraa M, Sprengers RW, van der Graaf Y, Peters CE, Moll FL, Verhaar MC . Autologous bone marrow-derived cell therapy in patients with critical limb ischemia: a meta-analysis of randomized controlled clinical trials. Ann Surg 2013; 258: 922\u2013929.","journal-title":"Ann Surg"},{"key":"BFhr2015134_CR110","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/sj.gt.3301678","volume":"9","author":"Y Taniyama","year":"2002","unstructured":"Taniyama Y, Tachibana K, Hiraoka K, Aoki M, Yamamoto S, Matsumoto K, Nakamura T, Ogihara T, Kaneda Y, Morishita R . Development of safe and efficient novel nonviral gene transfer using ultrasound: enhancement of transfection efficiency of naked plasmid DNA in skeletal muscle. Gene Ther 2002; 9: 372\u2013380.","journal-title":"Gene Ther"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/hr2015134.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/hr2015134","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/hr2015134.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T17:15:04Z","timestamp":1684430104000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/hr2015134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,3]]},"references-count":110,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["BFhr2015134"],"URL":"https:\/\/doi.org\/10.1038\/hr.2015.134","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,3]]},"assertion":[{"value":"18 August 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ryuichi Morishita, who is a founder of AnGes MG and a stock-holder, has IP of HGF gene therapy drug. The other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}